Interim Report 1-9/2018

24 Oct 2018 I The release and presentation materials are now available.

Read more

AGM 2019

The 2019 Annual General Meeting is planned to be held on 26 March 2019 in Helsinki.

Read more

ARAMIS trial results to be presented at ASCO GU

The results of the ARAMIS phase III trial of darolutamide in non-metastatic castration-resistant prostate cancer will be presented on 14 February 2019 at the Genitourinary Cancers Symposium (ASCO GU).

Read more

Orion has completed the sale of Orion Diagnostica business division

The Closing of the transaction took place on 30 April 2018.

Read more

Orion's R&D Pipeline

Orion's key research projects include three ongoing Phase III trials, among others.

Read more

Major shareholders by votes

Monthly updated list of Orion's major shareholders by votes.

Read more

Share information

Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.

Read more

Corporate Governance Statement

The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.

Read more

Orion Executive Management Board

The members of the Board of Directors

Annual Reports

Orion included in FTSE4Good Index

Orion Corporation has been included in the globally recognised FTSE4Good Index.

Read more